top of page

GCAP GENERIC DRUG FOR COVID-19
Molnupiravir (Lagevrio) is the first-ever investigational oral antiviral therapy for the treatment of SARS-CoV-2 (COVID-19) in non-hospitalized adult patients. It is a potent ribonucleoside analog that blocks SARS-CoV-2 replication by acting as a competitive substrate of virally-encoded RNA-dependent RNA polymerase.

DRUG INFORMATION
Molnupiravir
Coming Soon
FACTORY INFORMATION
COMING SOON

INQUIRY
Get Started Now

bottom of page